On November 5th, at the Merck Dongliang Xiangjin Expo, the company showcased outstanding achievements in innovative drugs, research pipelines, industrial cooperation, social responsibility, digitalization, and other fields. At the same time, Merck will join hands with various partners in the Chinese medical ecosystem to carry out a series of booth activities, demonstrating Merck's firm determination to deeply cultivate the Chinese market and share opportunities in the CIIE, and opening a new chapter of Merck China's "health sharing".
Anna Tian, Senior Vice President of Merck Global and President of Merck China, stated that China is a significant market for Merck globally. At this year's CIIE, Merck will showcase its journey of mutual growth with China's healthcare industry through numerous achievements. Merck expects to continue leveraging the spillover effects of the CIIE to bring more innovative drugs and solutions to China.
At this Expo, MSD will focus on displaying nearly 30 approved drugs and vaccines in China, covering tumor, diabetes, anti infection, rare diseases, anesthesia and other fields, and bringing global research pipelines. At present, Merck is conducting clinical research on multiple new drugs and indications across therapeutic fields in China, and is expected to introduce more than 40 new products and indications to China in the next five years.
It is reported that Merck has launched human papillomavirus (HPV), rotavirus, and pneumococcal vaccines in China, and is actively promoting the expansion of indications to cover more people and age groups. The company has built a rich pipeline of anti-tumor products and actively conducted clinical research on tumors in China, covering more than 20 high-risk cancer types such as lung cancer, liver cancer, and stomach cancer.
At the booth, MSD will also display a number of achievements made by working together with local partners, including the cooperation with Tongrun Biology, Kelenbotai, Peking University and Zhifei Biology. While bringing innovative treatment solutions to China, MSD will also help local innovation achievements go global.
In terms of animal health, Merck will showcase products and technological solutions covering five major businesses: pets, poultry, pigs, ruminants, and aquatic products. This is the "debut" of aquatic solutions after Merck completed the acquisition of Lilan Animal Health's aquatic business in July this year.
In the six day exhibition, MSD will hold 15 colorful activities covering vaccine, tumor, diabetes and rare diseases.